Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
635 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,688 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06087861 | 5-Day Preoperative Radiation for Soft Tissue Sarcoma | recruiting | Phase 2 | 75 | Stanford UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05910307 | Synovial Sarcoma Registry / Biospecimen Repository | recruiting | — | 1,000 | Children's Hospital of PhiladelphiaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02846987 |
| Study of Abemaciclib in Dedifferentiated Liposarcoma |
| active not recruiting |
| Phase 2 |
| 33 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Jun 8, 2026 |
| clinicaltrials |
| NCT05941325 | A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma | suspended | Phase 2 | 20 | Shanghai 6th People's HospitalOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06235125 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children(Cytalux) | recruiting | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | terminated | Phase 2 | 11 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT05167994 | Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）(SPARE-01) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06476704 | Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas(PRACTISS) | not yet recruiting | Phase 2 | 42 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07014137 | A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas | recruiting | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07188532 | Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial(BEAR) | recruiting | N/A | 141 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03823144 | Intravital Microscopy in Human Solid Tumors | recruiting | N/A | 85 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04832698 | Survey of Current Interventional and Diagnostic Imaging Residents After Participation in Endovascular Simulator Training | recruiting | — | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06022159 | A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.(HYPOSARC) | recruiting | Phase 2 | 48 | Institut Claudius RegaudOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07120945 | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)(Embrace Gyn) | active not recruiting | N/A | 70 | Medtronic - MITGINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07144254 | Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma | recruiting | Phase 1 | 24 | Emory UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07620431 | Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma | not yet recruiting | — | 55 | Peking University People's HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04123535 | Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma(HIFU-UPS) | terminated | N/A | 5 | Matthew BucknorOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04345003 | MR Elastography Parameters Impact on MR-HIFU Efficacy in Uterine Fibroids(ELASTUS) | completed | N/A | 40 | University Hospital, BordeauxOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT07615049 | Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation | not yet recruiting | Phase 3 | 296 | SWOG Cancer Research NetworkNETWORK | 0 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT07612098 | Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma(SPARE-04) | not yet recruiting | Phase 2 | 274 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03433183 | SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | completed | Phase 2 | 21 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609329 | Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas | recruiting | N/A | 100 | St. Anne's University Hospital Brno, Czech RepublicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07104331 | SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma | recruiting | Phase 2 | 41 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00077285 | Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma | active not recruiting | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03114527 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | active not recruiting | Phase 2 | 48 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04055753 | Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma | active not recruiting | — | 24 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04634227 | Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) | active not recruiting | Early Phase 1 | 30 | University of IowaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05225428 | Video Education With Result Dependent dIsclosure(VERDI) | recruiting | N/A | 1,020 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06113809 | Palbociclib and Pembrolizumab in Sarcoma | recruiting | Phase 1 | 8 | John RiethOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602049 | Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04087902 | Long-Term Longitudinal QoL in Patients Undergoing EEA | active not recruiting | — | 400 | Ohio State UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04634617 | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | active not recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05054335 | Patient-Specific Computational Walking Models in Improving Surgical and Rehabilitation Treatment in Patients With Pelvic Sarcomas | recruiting | N/A | 130 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2026source: clinicaltrials